Sign in with Google. Opens in new tab
bullish

BeOne

BeiGene (ONC US) - Strong FY25 guidance issued

238 Views03 Mar 2025 14:35
Broker
Robust product sales driven by zanubrutinib. BeiGene’s FY24 total product sales reached US$3.78bn (+73% YoY), in-line with our previous estimate.
What is covered in the Full Insight:
  • Introduction
  • Financial Performance Overview
  • Zanubrutinib's Market Impact
  • Competitive Landscape
  • Future Outlook
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 14-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x